AI Article Synopsis
- The HeartWare HVAD was successfully used as a temporary support system for eight children awaiting heart transplants between 2013 and 2015, mainly due to cardiomyopathy or complex single ventricle conditions.
- Out of these, one child experienced an operative death, but 87% (seven patients) were ultimately able to receive transplants.
- The average time these patients were on the HVAD support was about 24.5 days, and all transplanted patients remained alive and healthy during a follow-up period averaging around 448 days.
Article Abstract
The HeartWare HVAD has been used as a bridge to cardiac transplantation in the pediatric population. We describe outcomes following HeartWare HVAD implantation at a single center. A retrospective chart review was performed of all HeartWare HVAD implants performed at our institution between May 2013 and March 2015. Eight children between the ages of 9 and 17 years underwent HVAD implantation as a bridge to transplant (N = 7 cardiomyopathy, N = 1 complex single ventricle). There was one operative death in the complex single ventricle patient. Seven patients (87%) were successfully bridged to transplant. Median time of support was 24.5 days (range, 6-91 days). All transplanted patients are alive and well at a median follow-up of 448 days. Our results demonstrated that mechanical support with HeartWare HVAD is feasible in patients of varying sizes (from older children to adolescents).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/aor.12637 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!